Article by Bruce Sylvester A CAR (chimeric antigen receptor) T-cell therapy (idecabtagene vicleucel) more than triples the expected length of remission for multiple myeloma patients who have relapsed… read more.
Gilead Sciences announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for Trodelvy (sacituzumab govitecan-hziy) (SG) for the treatment of adult patients with… read more.
Genetic testing can uncover inherited genetic mutations, and could individualize cancer therapies, improve survival, manage cancer in loved ones and push the boundaries of precision medicine.
Interview and article by Christine Clark Modifications of cancer treatment regimens to reduce time spent in hospital, a drive-through pharmacy service and a technician-led virtual counselling clinic were… read more.
The majority of patients with follicular lymphoma (FL) have excellent results when treated with chemotherapy so — even with evolving understanding of disease biology and availability of a parade… read more.
Professor Stephen Ansell (Rochester, USA) discusses the DIAL study
Dr Graham Collins (Oxford, UK) discusses real-world data from patients treated with CD19 CAR-T in England. He then reviews data presented on the risk of fracture following front-line R-CHOP… read more.
Dr Steven Horwitz (New York, USA) discusses new directions for treating PTCL. Written by Thomas R. Collins.
Using rituximab in combination with chemotherapy — tailored based on risk profile and response speed — produced good results in children, adolescents and young adults with classic Hodgkin lymphoma,… read more.
Dr Alison J. Moskowitz (New York, USA) and Dr Graham Collins (Oxford, UK) review the long-term follow up data from brentuximabvedotin and nivolumab for R/R Hodgkin lymphoma Written by Thomas R. Collins
Dr Alison J. Moskowitz (New York, USA) highlights the long-term follow up data for single-agent brentuximab vedotin as pre-transplant salvage.
Dr Wendy Osborne (Newcastle upon Tyne, UK) highlights data coming from the H10 and AHL2011 trials. She then reviews data presented on the long-term follow up of the HD14… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
